From India to the World: United Biotech India’s Therapy Areas & Global Export Capabilities

April 19, 2026

Published by United Biotech India | Wednesday Pharma Series — Week 1 Reading Time: Approximately 12 minutes

The Global Medicine Access Challenge

Every day, millions of patients across Africa, Southeast Asia, the Middle East, and Central Asia are unable to access the medicines they need — not because those medicines do not exist, but because affordable, reliably manufactured supply has not reached them.

The World Health Organization estimates that more than 2 billion people worldwide lack consistent access to essential medicines. In low- and middle-income countries, patients living with cancer, heart disease, kidney failure, hormonal disorders, and bacterial infections face interrupted treatment, not due to a lack of clinical knowledge, but due to fractured supply chains, inadequate local manufacturing, and unaffordable pricing.

United Biotech India was established to address exactly this gap.

A WHO-GMP certified pharmaceutical manufacturer and exporter, United Biotech India has spent over two decades building a portfolio spanning 7 critical therapy areas, manufacturing infrastructure that meets international regulatory standards, and an active export network covering 60+ countries across four continents.

This article provides a comprehensive overview of our therapy areas, product categories, export footprint, quality commitments, and what partnering with United Biotech India means for distributors, hospital procurement teams, and government health agencies worldwide.

About United Biotech India

United Biotech India is a fully integrated pharmaceutical company — operating across the complete value chain from formulation development and manufacturing through to international export and regulatory support.

Our core philosophy has remained unchanged since our founding:

“Quality medicines must be accessible to every patient, in every market, at every economic level.”

This principle shapes every decision we make — from how we develop formulations and validate manufacturing processes, to how we price our products and support our international business partners.

At a Glance

Parameter	Details
Company Type	Pharmaceutical Manufacturer & Exporter
Manufacturing Certification	WHO-GMP Certified
Core Therapy Areas	7 Segments
Global Export Reach	60+ Countries
Key Export Regions	Africa, Southeast Asia, Middle East, CIS & Central Asia
Dosage Forms Available	Tablets, Capsules, Injectables, Oral Liquids, Hormonal Formulations
Regulatory Support Offered	CTD Dossiers, CoPP, Free Sale Certificates, Stability Data
Client Types	Distributors, Hospital Procurement, Govt. Tender Agencies, Import Partners

👉 Explore our complete product portfolio — www.unitedbiotechindia.com/products

Our 7 Core Therapy Areas

🎗️ 1. Oncology

The Global Cancer Burden

The International Agency for Research on Cancer (IARC) projects that by 2040, the world will face 30 million new cancer cases per year — a 47% rise from today. The sharpest growth will occur in low- and middle-income countries, where oncology drug access is most constrained by infrastructure limitations and originator drug pricing.

Affordable, quality-manufactured oncology medicines are not simply a commercial segment. They are a clinical and humanitarian necessity.

Our Oncology Product Categories

United Biotech India’s oncology portfolio covers the following clinical categories:

Cytotoxic Chemotherapy Agents A comprehensive range covering alkylating agents, antimetabolites, anthracyclines, vinca alkaloids, taxanes, and platinum-based compounds — aligned with international treatment protocols for both solid tumour and haematological malignancy management.

Hormonal Cancer Therapies Selective oestrogen receptor modulators, aromatase inhibitors, and androgen deprivation therapy agents — for hormone-sensitive cancer management including breast and prostate cancer.

Supportive Oncology Care Agents Anti-emetic formulations, haematopoietic growth factor support, bone-protective agents, and corticosteroid-based supportive therapy — essential companions to active chemotherapy regimens.

Cytoprotective Agents Formulations used to manage and mitigate organ toxicity associated with intensive chemotherapy protocols — improving patient safety and treatment tolerability.

Key Export Markets — Oncology

👉 Contact us for oncology product enquiries

💉 2. Injectables

Market Context

The global pharmaceutical injectables market exceeds $700 billion in value and is expanding at a CAGR of over 11%. Injectables are the primary pharmaceutical delivery route in hospital, surgical, emergency, and intensive care settings — making supply reliability an absolute clinical requirement.

India’s injectable pharmaceutical exports crossed $3 billion in FY2023, with WHO-GMP certified manufacturers like United Biotech India at the centre of that export growth.

Our Injectable Product Categories

Antibiotic Injectables Injectable antibiotic formulations spanning cephalosporin classes (all generations), beta-lactam and beta-lactamase inhibitor combinations, carbapenem-class agents, aminoglycosides, and nitroimidazole injectables — covering community-acquired through to severe nosocomial infection management.

Analgesic & Anti-inflammatory Injectables NSAID analgesic agents, opioid analgesics, and combination pain management formulations for post-operative, trauma, and palliative care settings.

Vitamin & Micronutrient Injectables Water-soluble vitamin complexes, antioxidant therapy formulations, and intravenous iron preparations — for nutritional deficiency management where oral supplementation is clinically inadequate.

Cardiovascular & Haemodynamic Injectables Loop diuretics, inotropic and vasopressor agents, and antiarrhythmic injectable formulations for acute cardiovascular management in hospital environments.

Metabolic & Endocrine Injectables Corticosteroid and metabolic support injectables for acute inflammatory, adrenal, and endocrine emergency management.

Antifungal Injectables Systemic antifungal injectable agents for serious fungal infection management in immunocompromised and critically ill patients.

Injectable Quality Standards — Every Batch

✅ Sterility testing per BP / USP / IP pharmacopoeial standards ✅ Particulate matter analysis — sub-visible and visible ✅ Bacterial endotoxin (LAL) / pyrogen testing ✅ Container-closure integrity testing ✅ Validated aseptic fill-finish under ISO-classified cleanroom conditions ✅ ICH-compliant accelerated and long-term stability studies

Key Export Markets — Injectables

🏥 3. Critical Care

Why Critical Care Supply Cannot Fail

The WHO estimates that low-income countries have just 0.1 to 2.5 ICU beds per 100,000 population — compared to over 20 in high-income nations. In these settings, when critical care infrastructure exists, the medicines that support it must be available, potent, and unfailingly reliable. A stock-out in an ICU is not an operational inconvenience — it is a clinical emergency.

Our Critical Care Product Categories

Vasopressor & Haemodynamic Support Agents A range of vasopressor and inotropic formulations for circulatory shock, haemodynamic instability, and septic shock management — standard requirements in any functioning intensive care unit.

Sedation, Analgesia & Anaesthetic Support Agents Benzodiazepine sedatives, short-acting anaesthetic agents, opioid analgesics, and neuromuscular blocking agents for ventilated and procedurally sedated patients.

Electrolyte & Acid-Base Correction Agents Injectable electrolyte concentrates and metabolic acid-base correction formulations for electrolyte imbalance and metabolic disorder management — daily requirements in any ICU.

Anticoagulation Agents Unfractionated and low-molecular-weight heparin formulations for VTE prophylaxis and treatment, and dialysis circuit anticoagulation.

Anti-seizure & Neurological Emergency Agents Injectable anticonvulsant formulations for acute status epilepticus and neurological emergency management in critically ill patients.

Respiratory & Bronchodilator Support Bronchodilator and mucolytic formulations, and respiratory support agents for acute respiratory failure and bronchospasm management.

Key Export Markets — Critical Care

❤️ 4. Cardiology

The World’s Leading Cause of Death

Cardiovascular diseases cause 17.9 million deaths annually — representing 32% of all global deaths (WHO, 2021). In developing markets, this burden is compounded by inconsistent access to maintenance medications. Patients who cannot sustain their cardiovascular therapy are at persistent risk of preventable cardiac events.

Our Cardiology Product Categories

Antihypertensive Agents A comprehensive antihypertensive range spanning calcium channel blockers, angiotensin receptor blockers (ARBs), ACE inhibitors, beta-blockers, and diuretic agents — covering all major treatment pathways at primary and secondary care levels.

Lipid-Lowering Agents Statin-class formulations across multiple potency levels, fibrate-class agents, cholesterol absorption inhibitors, and fixed-dose combination lipid-lowering products for dyslipidaemia management and cardiovascular risk reduction.

Antiplatelet & Antithrombotic Agents Single and dual antiplatelet therapy formulations, and oral anticoagulant agents for the prevention and management of acute coronary syndrome, stroke, and thromboembolic events.

Heart Failure Management Agents Diuretics, aldosterone antagonists, cardiac glycosides, and rate-modulating agents for acute and chronic heart failure management across functional classifications.

Antiarrhythmic Agents Oral and injectable antiarrhythmic formulations across multiple drug classes for ventricular and supraventricular arrhythmia management including atrial fibrillation.

Antianginal Agents Nitrate-class formulations in sublingual, oral, and transdermal presentations for acute relief and long-term prevention of angina pectoris.

Key Export Markets — Cardiology

👉 Enquire about our cardiology product range

🫘 5. Nephrology

The Silent Global Epidemic

Chronic Kidney Disease (CKD) affects an estimated 850 million people worldwide (ISN, 2023) — more than diabetes and cancer combined — yet remains one of the most under-resourced therapy areas in developing markets. Limited dialysis access, rare transplantation opportunities, and inconsistent medication supply create a significant unmet clinical need.

Our Nephrology Product Categories

CKD Progression Management Agents Renin-angiotensin system blocking agents, oral acid-base correctors, and active Vitamin D analogues for slowing CKD progression and managing the metabolic consequences of declining kidney function across disease stages 1 through 5.

Renal Anaemia Management Intravenous iron formulations in multiple presentation types and haemopoietic support agents for anaemia management in CKD patients on and off dialysis.

Phosphate & Mineral Metabolism Agents Calcium-based and non-calcium-based phosphate binders, and calcimimetic agents for controlling hyperphosphataemia and secondary hyperparathyroidism in dialysis patients.

Dialysis Support Medications Anticoagulation agents for haemodialysis circuit management, and electrolyte correction formulations compatible with renal replacement therapy protocols.

Renal Vitamin Supplementation Water-soluble vitamin complexes specifically formulated for dialysis patients — addressing the loss of water-soluble vitamins during each haemodialysis session.

Key Export Markets — Nephrology

🦠 6. Antibiotics

Responsible Manufacturing in an Era of AMR

The WHO identifies antimicrobial resistance (AMR) as one of the greatest threats to global public health — with drug-resistant infections projected to cause 10 million deaths per year by 2050 if current trends continue. Substandard, under-dosed, and poorly formulated antibiotic products are a significant driver of resistance development.

This is why who manufactures an antibiotic matters as much as how it is prescribed.

United Biotech India manufactures every antibiotic product under verified WHO-GMP conditions — ensuring full stated potency, pharmacopoeial dissolution compliance, and shelf-life stability throughout the international supply journey.

Our Antibiotic Product Categories

Penicillin & Beta-Lactam Combination Class Broad and narrow-spectrum penicillin formulations and beta-lactam/beta-lactamase inhibitor combinations in oral and injectable forms — for community-acquired and hospital-acquired infection management.

Cephalosporin Class — All Generations First through fourth-generation cephalosporin formulations in oral and injectable presentations — spanning community-acquired infections through to nosocomial and febrile neutropenia management.

Carbapenem Class Broad-spectrum carbapenem injectable formulations reserved for serious multi-drug resistant nosocomial infections in hospital settings.

Macrolide Class Oral and injectable macrolide formulations for respiratory tract infections, atypical bacterial pathogens, and related clinical indications.

Fluoroquinolone Class Oral and injectable fluoroquinolone formulations for urinary tract, respiratory, gastrointestinal, and systemic bacterial infection management.

Nitroimidazole Class Oral and injectable nitroimidazole formulations for anaerobic bacterial infections and protozoal conditions prevalent in tropical export markets.

Aminoglycoside Class Injectable aminoglycoside formulations for gram-negative bacterial infection management under therapeutic drug monitoring protocols.

Anti-tuberculosis Agents First-line anti-TB agents in single and fixed-dose combination (FDC) presentations — formulated per WHO DOTS programme specifications for national tuberculosis control programme use.

Antifungal Agents Oral and injectable antifungal agents across azole and polyene classes for superficial and systemic fungal infection management.

All antibiotic products are packaged in tropical-grade, moisture-resistant formats ensuring stability under the high-temperature, high-humidity conditions of our primary African and Southeast Asian export markets.

Key Export Markets — Antibiotics

⚗️ 7. Hormonal Therapies

A Fast-Growing Global Need

Hormonal disorders affect hundreds of millions of people worldwide — many undiagnosed. The WHO estimates 200 million people live with thyroid disease globally, while PCOS affects approximately 1 in 10 women of reproductive age. Hormonal cancers, adrenal disorders, diabetes-linked endocrine imbalances, and male hypogonadism further expand this clinical landscape.

Across our export markets in Southeast Asia, Africa, and the Middle East, rising health awareness and expanding primary care infrastructure are creating rapid demand growth for quality, affordable hormonal formulations.

Our Hormonal Therapy Product Categories

Thyroid Disorder Management Thyroid hormone replacement agents and antithyroid formulations in multiple strengths — for titrated management of both hypothyroidism and hyperthyroidism including pregnancy-safe options.

Women’s Reproductive Health Combined and progestogen-only oral contraceptive formulations, injectable contraceptive preparations, progesterone support formulations for luteal phase and pregnancy maintenance, and ovulation induction agents — covering the full breadth of female reproductive health pharmacotherapy.

Menopause & Hormone Replacement Therapy Oestrogen-only and combined oestrogen-progestogen HRT formulations for menopausal symptom management and postmenopausal health maintenance.

Adrenal & Corticosteroid Therapies Glucocorticoid and mineralocorticoid replacement formulations in oral and injectable presentations — for adrenal insufficiency, autoimmune disorders, and acute inflammatory conditions.

Diabetes & Metabolic Hormonal Management Human insulin formulations across rapid-acting, intermediate-acting, and premixed presentations, oral hypoglycaemic agents across multiple drug classes, and fixed-dose oral combination products — for comprehensive type 2 diabetes formulary requirements.

Men’s Health & Andrology Testosterone replacement formulations, 5-alpha reductase inhibitors, alpha-blockers for prostatic conditions, and phosphodiesterase inhibitor agents for male hormonal health, benign prostatic hyperplasia, and related conditions.

Key Export Markets — Hormonal Therapies

👉 View our complete hormonal therapy product range

Our Global Export Network — 60+ Countries, 4 Continents

United Biotech India’s international presence is the result of two decades of deliberate market development, regulatory investment, and relationship-building with distributors, hospitals, tender agencies, and government health ministries worldwide.

🌍 Africa

West Africa: Nigeria, Ghana, Senegal, Côte d’Ivoire, Cameroon, Sierra Leone East Africa: Kenya, Ethiopia, Tanzania, Uganda, Rwanda, Djibouti North Africa: Algeria, Egypt, Libya, Sudan, Morocco, Tunisia Southern Africa: Zimbabwe, Zambia, Mozambique, Madagascar

🌏 Southeast & South Asia

🌐 Middle East

🌎 CIS & Central Asia

What Our Export Partners Receive

A partnership with United Biotech India is a comprehensive commercial, regulatory, and supply relationship — not a transactional interaction.

📋 Regulatory & Documentation Support

Complete CTD dossiers per ICH M4 format for product registration
Country-specific registration guidance and document preparation
Certificate of Pharmaceutical Product (CoPP) from CDSCO, India
WHO-GMP Certificates and manufacturer authorisation letters
Free Sale Certificates for import registration requirements
Stability data per ICH Q1A — Zone IVb (40°C / 75% RH) for tropical markets
Batch Certificate of Analysis (COA) with complete pharmacopoeial test results
MSDS for all formulations

📦 Supply Chain & Logistics

Flexible MOQ structures for new market entry
FOB, CIF, CFR, CNF pricing as per importer preference
Cold chain packaging for temperature-sensitive products
Tropical-grade packaging for high-temperature, high-humidity climate stability
Complete shipping documentation — packing list, COO, airway bill, bill of lading

🤝 Commercial Partnership Support

Dedicated International BD representatives per region
Long-term supply agreements with pricing stability provisions
Samples for product registration and tender qualification
Product monographs and technical data sheets for formulary submissions
RFQ response within 24–48 business hours
Marketing support materials — visual aids and product catalogues

India’s Pharmaceutical Advantage — Why It Matters for You

When you source from United Biotech India, you access not just one manufacturer’s capability — you access the structural advantages of India’s entire pharmaceutical ecosystem.

India supplies 20% of global generic drug exports by volume — the world’s highest
India’s pharmaceutical exports reached $27.9 billion in FY2024
India holds the highest number of US FDA-approved manufacturing plants outside the USA
India produces 60% of the world’s vaccines
India’s pharma export market is projected to reach $65 billion by 2030

This ecosystem gives United Biotech India access to qualified APIs, experienced pharmaceutical talent, regulatory institutional knowledge, and established global logistics infrastructure — all of which translate directly into better value for our international partners.

Our Quality Commitment — Non-Negotiable at Every Stage

Quality at United Biotech India is not a department or a checkbox. It is a culture embedded across every function.

🔬 Raw Material Control Every API and excipient is sourced from approved vendors and fully tested for identity, purity, potency, and microbial limits before entering manufacturing. No material enters production without complete qualification.

🏭 Manufacturing Control All processes are validated, documented, and executed under qualified pharmaceutical professional supervision — in strict WHO-GMP compliance. Deviations are investigated and resolved under a robust CAPA framework.

🧪 Finished Product Quality Control Every batch is tested for appearance, identification, assay, dissolution, related substances, content uniformity, and microbial limits before release. No batch leaves our facility without full QA sign-off.

📦 Stability Assurance Products are placed on formal ICH stability programs with real-time and accelerated data confirming shelf-life claims under Zone IVb (40°C / 75% RH) — directly relevant to our tropical and subtropical export markets.

📋 Complete Batch Traceability Every released batch is fully traceable through raw material COAs, in-process records, environmental monitoring data, and a complete Certificate of Analysis. Full documentation is provided with every shipment.

This is not compliance for the sake of certification. It is our commitment to every patient who depends on a United Biotech India product.

Looking Ahead — United Biotech India’s Growth Roadmap

India’s pharmaceutical export market is projected to reach $65 billion by 2030. United Biotech India is an active contributor to this growth trajectory — not a passive observer.

Our strategic priorities include:

✅ Geographic expansion into Latin American and Francophone African markets ✅ Strengthening our oncology and specialty portfolio registration across key markets ✅ EU-GMP alignment through progressive manufacturing infrastructure investment ✅ Deeper engagement with government tender programmes across Asia and Africa ✅ Building digital procurement partnerships to reduce friction for international buyers

Our mission remains unchanged: Quality medicines. Global access. Indian manufacturing excellen

Start a Partnership with United Biotech India

Whether you are a pharmaceutical distributor, hospital procurement team, government health ministry, import agent, or tender agency — our international business team is ready to engage with you.

We are ready to discuss: ✅ Product category availability, specifications and MOQs ✅ FOB / CIF / CNF pricing for your specific market ✅ Regulatory dossier availability and registration support ✅ Samples for product registration or tender qualification ✅ Long-term supply partnership structures ✅ Private label and contract manufacturing enquiries

📬 Contact United Biotech India

🌐 Website: www.unitedbiotechindia.com
📧 Email Enquiry: https://unitedbiotechindia.com/contact-us/
📋 Product Catalogue: www.unitedbiotechindia.com/products
📍 Headquarters: India